Floris E J Jolink, Marisa Onrust, Dinis Dos Reis Miranda, Loes Mandigers, Thijs Delnoij, Jacinta J Maas, S Jorinde Raasveld, Alexander P J Vlaar, Dirk W Donker, Erik Scholten, Jesse de Metz, Judith van den Brule, Marijn Kuijpers, Karin M Vermeulen, Peter H J van der Voort, Walter M van den Bergh, Annemieke Oude Lansink-Hartgring
{"title":"体外膜氧合后5年：健康相关生活质量和患者预后的前瞻性队列研究","authors":"Floris E J Jolink, Marisa Onrust, Dinis Dos Reis Miranda, Loes Mandigers, Thijs Delnoij, Jacinta J Maas, S Jorinde Raasveld, Alexander P J Vlaar, Dirk W Donker, Erik Scholten, Jesse de Metz, Judith van den Brule, Marijn Kuijpers, Karin M Vermeulen, Peter H J van der Voort, Walter M van den Bergh, Annemieke Oude Lansink-Hartgring","doi":"10.1097/CCM.0000000000006900","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To report on 5-year survival, health-related quality of life (HRQoL), and occupational status of patients with respiratory or cardiac failure, who were supported with extracorporeal membrane oxygenation (ECMO).</p><p><strong>Design: </strong>A prospective multicenter observational cohort follow-up study.</p><p><strong>Setting: </strong>ICUs of ten ECMO centers in the Netherlands, representing more than 90% of all patients supported with ECMO in the Netherlands.</p><p><strong>Patients: </strong>Patients supported with ECMO between August 2017 and July 2019.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Survival was assessed by consulting the Dutch municipal records database. All 5-year survivors received a questionnaire. HRQoL was assessed using the standardized EuroQol 5D Five Levels instrument, and occupational status was assessed using the standardized Institute for Medical Technology Assessment Productivity Cost Questionnaire. Of the initial 428 participants, 230 (54%) survived the hospital admission, 213 (50%) survived the first year, and 155 (36%) survived 5 years. Five-year survival rates were 42% for patients receiving ECMO for respiratory support, 39% for cardiac support, and 25% for extracorporeal cardiopulmonary resuscitation. The response rate to the questionnaire was 72%. HRQoL was rated satisfactory at 5 years, with a median EuroQol index of 0.82 (interquartile range, 0.73-0.98). Five-year survivors reported slight-to-moderate impairment of mobility (39%), impairment of usual activities (44%), and pain or discomfort (60%). After 5 years, the majority of patients were either employed (41%), retired (31%), or permanently declared unfit for work (26%).</p><p><strong>Conclusions: </strong>Long-term outcome in patients supported with ECMO is good. Five-year survivors reported that HRQoL was satisfactory despite some impairment in day-to-day functioning.</p>","PeriodicalId":10765,"journal":{"name":"Critical Care Medicine","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Five Years After Extracorporeal Membrane Oxygenation: A Prospective Cohort Study of Health-Related Quality of Life and Patient Outcomes.\",\"authors\":\"Floris E J Jolink, Marisa Onrust, Dinis Dos Reis Miranda, Loes Mandigers, Thijs Delnoij, Jacinta J Maas, S Jorinde Raasveld, Alexander P J Vlaar, Dirk W Donker, Erik Scholten, Jesse de Metz, Judith van den Brule, Marijn Kuijpers, Karin M Vermeulen, Peter H J van der Voort, Walter M van den Bergh, Annemieke Oude Lansink-Hartgring\",\"doi\":\"10.1097/CCM.0000000000006900\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To report on 5-year survival, health-related quality of life (HRQoL), and occupational status of patients with respiratory or cardiac failure, who were supported with extracorporeal membrane oxygenation (ECMO).</p><p><strong>Design: </strong>A prospective multicenter observational cohort follow-up study.</p><p><strong>Setting: </strong>ICUs of ten ECMO centers in the Netherlands, representing more than 90% of all patients supported with ECMO in the Netherlands.</p><p><strong>Patients: </strong>Patients supported with ECMO between August 2017 and July 2019.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Survival was assessed by consulting the Dutch municipal records database. All 5-year survivors received a questionnaire. HRQoL was assessed using the standardized EuroQol 5D Five Levels instrument, and occupational status was assessed using the standardized Institute for Medical Technology Assessment Productivity Cost Questionnaire. Of the initial 428 participants, 230 (54%) survived the hospital admission, 213 (50%) survived the first year, and 155 (36%) survived 5 years. Five-year survival rates were 42% for patients receiving ECMO for respiratory support, 39% for cardiac support, and 25% for extracorporeal cardiopulmonary resuscitation. The response rate to the questionnaire was 72%. HRQoL was rated satisfactory at 5 years, with a median EuroQol index of 0.82 (interquartile range, 0.73-0.98). Five-year survivors reported slight-to-moderate impairment of mobility (39%), impairment of usual activities (44%), and pain or discomfort (60%). After 5 years, the majority of patients were either employed (41%), retired (31%), or permanently declared unfit for work (26%).</p><p><strong>Conclusions: </strong>Long-term outcome in patients supported with ECMO is good. Five-year survivors reported that HRQoL was satisfactory despite some impairment in day-to-day functioning.</p>\",\"PeriodicalId\":10765,\"journal\":{\"name\":\"Critical Care Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Care Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/CCM.0000000000006900\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCM.0000000000006900","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Five Years After Extracorporeal Membrane Oxygenation: A Prospective Cohort Study of Health-Related Quality of Life and Patient Outcomes.
Objectives: To report on 5-year survival, health-related quality of life (HRQoL), and occupational status of patients with respiratory or cardiac failure, who were supported with extracorporeal membrane oxygenation (ECMO).
Design: A prospective multicenter observational cohort follow-up study.
Setting: ICUs of ten ECMO centers in the Netherlands, representing more than 90% of all patients supported with ECMO in the Netherlands.
Patients: Patients supported with ECMO between August 2017 and July 2019.
Interventions: None.
Measurements and main results: Survival was assessed by consulting the Dutch municipal records database. All 5-year survivors received a questionnaire. HRQoL was assessed using the standardized EuroQol 5D Five Levels instrument, and occupational status was assessed using the standardized Institute for Medical Technology Assessment Productivity Cost Questionnaire. Of the initial 428 participants, 230 (54%) survived the hospital admission, 213 (50%) survived the first year, and 155 (36%) survived 5 years. Five-year survival rates were 42% for patients receiving ECMO for respiratory support, 39% for cardiac support, and 25% for extracorporeal cardiopulmonary resuscitation. The response rate to the questionnaire was 72%. HRQoL was rated satisfactory at 5 years, with a median EuroQol index of 0.82 (interquartile range, 0.73-0.98). Five-year survivors reported slight-to-moderate impairment of mobility (39%), impairment of usual activities (44%), and pain or discomfort (60%). After 5 years, the majority of patients were either employed (41%), retired (31%), or permanently declared unfit for work (26%).
Conclusions: Long-term outcome in patients supported with ECMO is good. Five-year survivors reported that HRQoL was satisfactory despite some impairment in day-to-day functioning.
期刊介绍：
Critical Care Medicine is the premier peer-reviewed, scientific publication in critical care medicine. Directed to those specialists who treat patients in the ICU and CCU, including chest physicians, surgeons, pediatricians, pharmacists/pharmacologists, anesthesiologists, critical care nurses, and other healthcare professionals, Critical Care Medicine covers all aspects of acute and emergency care for the critically ill or injured patient.
Each issue presents critical care practitioners with clinical breakthroughs that lead to better patient care, the latest news on promising research, and advances in equipment and techniques.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
